OVX-033 is under clinical development by Osivax and currently in Phase I for Coronavirus Disease 2019 (COVID-19).

OVX-836 is under clinical development by Osivax and currently in Phase II for Unspecified Influenza Virus Infections.

INR:0084. pakistan vs bangladesh t20 Zhimeng Pharmaceuticals' anti-HBV nucleocapsid inhibitor ZM-H1505R was approved for clinical trials Big news for c ...

INR:7791. india versus australia t20 world cup live AbbVie/Roche's Venclexta+Gazyva combination for CLL approved in Canada ...

Crown Perth Sports Bar schedule Eli Lilly's Cyramza combined with erlotinib is approved by the FDA for first-line treatment of EGFR-muta ...

INR:5127. world cup final 2024 venue Zhimeng Pharmaceuticals' anti-HBV nucleocapsid inhibitor ZM-H1505R was approved for clinical trials Endoscope lead ...

12月23日，贵州大学绿色农药全国重点实验室博士生王艳菊在Aggregate (影响因子IF=13.9)期刊发表了题为“A Vanillin‐Derived Inhibitor of Aggregates via Targeting ...

Molecular Science and Biomedicine Laboratory (MBL), State Key Laboratory of Chemo/Biosensing and Chemometrics, College of Chemistry and Chemical Engineering, College of Biology, Aptamer Engineering ...

This cover highlights the article ZBTB48 is a priming factor regulating B-cell-specific CIITA expression by Grishma Rane, Dennis Kappei and colleagues. The study identifies how ZBTB48, represented as ...

To this end, a barcoded eVLP capsid library containing 3,762 single-residue mutants of MMLV Gag protein capsid and nucleocapsid domains in the Gag-ABE cargo was generated. This barcoded library ...

The intrinsic flexibility of nucleocapsids usually prevents their full-length structural characterisation at high resolution. Here, we describe purification of full-length recombinant metastable ...